Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021

Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
Novartis announced the introduction of T-Charge™, the company’s next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. At the 63rd American Society of Hematology Annual Meeting & Exposition (ASH) 2021, Novartis will present early clinical data from ongoing Phase I clinical trials with YTB323 (anti-CD19) and PHE885 (anti-BCMA),